

Active substances set

Search phrase: tisagenlecleucel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute lymphoid leukemia

Tisagenlecleucel is indicated for the treatment of
paediatric and young adult patients up to and including 25

Tisagenlecleucel years of age with B-cell acute lymphoblastic leukaemia
(ALL) that is refractory, in relapse post-transplant or in
second or later relapse.

✓ **FULL
REIMBURSEMENT**

✓ **ESMO**